Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

ViaMune

Immunotherapies to treat cancer

ViaMune is developing an immunotherapy vaccine targeting tumor-specific MUC1, a cell-surface glycoprotein that helps cancerous cells form a barrier against chemotherapeutic drugs.

ViaMune’s lead compound — MTI, still in the pre-clinical stage — promises to target aberrant MUC1 specifically and defeat tolerance to tumor antigens, aiding in tumor treatment.

The company is investigating related tumor-associated glycoproteins to expand its drug therapy pipeline.